Soleno Therapeutics Announces The Appointment Biopharma Veteran Mark W. Hahn To Its Board Of Directors To Strengthen Strategic Leadership
Soleno Therapeutics appoints Mark W. Hahn as independent director, adding seasoned financial leadership to its Board.
Breaking News
Oct 14, 2025
Simantini Singh Deo
20251014174703.png)
Soleno Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapeutics for rare diseases, has announced the appointment of Mark W. Hahn as an independent director to its Board of Directors and as a member of its Audit Committee. With this appointment, the Soleno Board now consists of seven members. Mark Hahn is a seasoned finance executive with nearly 30 years of experience serving in Chief Financial Officer roles within the life sciences sector.
Throughout his career, he has played a pivotal role in driving company growth through successful product launches, fundraising, and mergers and acquisitions. His extensive background in financial leadership, particularly in companies developing therapies for rare and serious diseases, is expected to provide valuable guidance as Soleno advances its commercial operations.
Commenting on the appointment, Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics, said, “We are delighted to welcome Mark to the Soleno Board as we continue to execute a strong commercial launch of VYKAT™ XR. His broad and diverse experience as a financial leader, especially with commercial-stage rare disease companies, aligns perfectly with Soleno’s current focus and long-term vision. I look forward to working closely with Mark as we strengthen our business and expand the reach of VYKAT™ XR.”
Expressing his enthusiasm about joining the company, Mark Hahn said, “Having witnessed the life-changing impact that innovative therapies can bring to people living with rare diseases, I am truly excited to join Soleno at this important stage of its growth. I look forward to collaborating with Anish, the Board, and the leadership team to help maximize the reach of VYKAT™ XR and make a meaningful difference for the Prader-Willi syndrome community, including patients, caregivers, and healthcare providers.”
Before joining the Soleno Board, Mr. Hahn served as Chief Financial Officer of Verona Pharma PLC from March 2020 through the phase 3 program and the successful launch of its first approved product, until the company’s acquisition by Merck & Co., Inc. for approximately $10 billion in October 2025. Prior to that, he was CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum (Sobi) for up to $915 million in November 2019. During his time there, he helped raise capital and led the launch of Dova’s first commercial rare disease therapy.
Earlier in his career, Mr. Hahn served as CFO of Cempra, Inc. from 2010 until its acquisition by Melinta Therapeutics in 2017, where he successfully led the company’s initial public offering and multiple follow-on financings. He has also held CFO positions at several other public and private companies and began his professional journey at Ernst & Young. In addition to his new role at Soleno, Mr. Hahn serves as a Board member and Audit Committee Chair at Opterion Health AG. He holds a Bachelor of Business Administration degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a Certified Public Accountant in Maryland and North Carolina.